Following successful Phase 3 trials, the US FDA has approved Reltecimod from Israel’s Atox Bio (reported here previously) for the treatment of NSTI (Necrotizing  Soft  Tissue Infections), commonly referred to as flesh-eating bacteria. (fast-tracked in 2012!) https://www.atoxbio.com/wp-content/uploads/2020/12/Atox-Bio-Reltecimod-NDA-Filing-PR-Dec-10-2020-FINAL.pdf

The US Biomedical R&D Authority has awarded Israel’s Atox Bio $24 million to develop its treatments for severe infections.  Atox Bio’s AB103 uniquely modulates the patient’s immune response rather than attacking the virus or bacteria. Pathogens cannot develop resistance to … Continue reading →

Israel’s Atox Bio announced the success of Phase Iia clinical trials of its AB103 treatment of Necrotizing Soft Tissue Infections (NSTI). NSTIs are life-threatening bacterial infections with significant morbidity and high mortality rate. http://www.globes.co.il/serveen/globes/docview.asp?did=1000799752&fid=1725

Israeli bio-tech Atox Bio announced that the US Food and Drug Administration has granted fast track designation to its lead product AB103, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI). Currently, there are no approved treatments … Continue reading →